Factor V Leiden
- 1 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Dimensions of Critical Care Nursing
- Vol. 41 (4) , 190-199
Abstract
Background: Factor V Leiden (FVL) is a hereditary thrombophilia, which causes the blood to be more hypercoagulable; in essence, the blood tends to clot more easily, especially under certain circumstances. It is the most common genetic mutation, causing thrombophilia in patients of white background. Patients that have FVL are at a higher risk to develop venous thromboembolism (VTE) after surgery and trauma. Objective: The purpose of this review is to identify FVL as a risk factor, which may impede optimum acute cardiopulmonary management which may contribute to a longer length of stay (LOS) in the hospital. Methods: This article is a systematic review of the literature involving research printed in peer-reviewed journals from 2015 to 2018. The University of Tennessee Health Science Center online library, PubMed, and Google Scholar were used for the literature search. Results: The results of this study determined that although FVL is in fact a risk factor, which may impede optimum acute cardiopulmonary management which may contribute to a longer LOS, management of VTE is no different for a person with FVL compared with those without FVL. Conclusion: Factor V Leiden is a risk factor for the development of VTE, specifically deep vein thrombosis, in surgical, trauma, pregnant, and hormone replacement therapy patients, thus increasing LOS and recurrence of such events. Regardless of FVL status, management of VTE should be initiated promptly and discontinued when appropriate.Keywords
This publication has 12 references indexed in Scilit:
- Hereditary thrombophilia in trauma patients with venous thromboembolism: Is routine screening necessary?Journal of Trauma and Acute Care Surgery, 2018
- Thrombophilia Testing and Venous ThrombosisNew England Journal of Medicine, 2017
- Onset of Coagulation Function Recovery Is Delayed in Severely Injured Trauma Patients with Venous ThromboembolismJournal of the American College of Surgeons, 2017
- Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of AnticoagulationThe American Journal of Medicine, 2017
- Individual clotting factor contributions to mortality following traumaJournal of Trauma and Acute Care Surgery, 2017
- Lifetime Risk of Venous Thromboembolism in Two Cohort StudiesThe American Journal of Medicine, 2016
- Guidance for the evaluation and treatment of hereditary and acquired thrombophiliaJournal of Thrombosis and Thrombolysis, 2016
- Factor V Leiden, Prothrombin and MTHFR Mutation in Patients with Preeclamsia, Intrauterine Growth Restriction and Placental AbruptionOpen Access Macedonian Journal of Medical Sciences, 2015
- An International Normalized Ratio–Based Definition of Acute Traumatic Coagulopathy Is Associated With Mortality, Venous Thromboembolism, and Multiple Organ Failure After InjuryCritical Care Medicine, 2015
- Surgical Duration and Risk of Venous ThromboembolismJAMA Surgery, 2015